BÁO CÁO Y HỌC: "IS THE WAY TO MAN’S HEART (AND LUNG) THROUGH THE ABDOMEN" DOC

This study was conducted among female subjects to assess the possible association between selected risk factors and lung function as well as airway symptoms in a 32-year perspective. The Prospective Population Study of Women was initiated in 1968-1969 in Göteborg, Sweden (population about 450 000) w[r]

Int. J. Med. Sci. 2007, 4 53International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2007 4(1):53-58 © Ivyspring International Publisher. All rights reserved Research Paper Does Flavanol Intake Influence Mortality from Nitric Oxide-Dependent Processes? Ischemic Heart Disease, Stroke,[r]

18. Farci P, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med, 1996. 335(9): 631-4. 19. Vogt M, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med, 1999.[r]

n 342 219 211 8 chd present 81 71 70 1 0.033 BMI (kg/m²) 22.1±1.5 22.9±1.3 22.9±1.1 23.1±1.1 0.023 Cholesterol (mg/dl) 270.5±51.2 266.2±89.4 266.4±93.2 262±64.5 ns LDL 183±46.8 189±54.8 194±53.9 174.6±62.5 ns HDL 65.5±20.6 53.5±16 54±16 58.2±17.8 0.004 VLDL 22±13.2 23±8.8 23.4±8.8 19.2±4.8 ns Trigly[r]

tion. Exercise is a known stress condition that con-sumes muscle glycogen rapidly. During the recovery period following exercise, the whole-body glucose tolerance and the rate of muscle glycogen storage in-creases simultaneously, resulting in glycogen super-compensation [5]. This normal adaptation s[r]

6. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65(4):1416–1421. 7. Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funa[r]

respective Rice-fluid) physiological saline solution, respectively. The cultures were incubated with gentle shaking at 37°C in a microaerophilic atmosphere. Samples (100μl) for viability measurement were taken at various points of time, that is, 30min., 60min., and 120min., respectively. Viability w[r]

The Q statistic was considered significant for P&lt;0.10 [30, 31]. Publication bias is always a concern in meta-analysis. The presence of publication bias indi-cates that nonsignificant or negative findings remain unpublished. To test for publication bias, both Begg's [32] and Egger's<[r]

Xem Thêm " EPIDEMIOLOGIC CHARACTERISTICS AND RISK FACTORS FOR RENAL CELL CANCER "

Xem Thêm " JOB ANALYSIS AND EVALUATION "

Int. J. Med. Sci. 2006, 3 75International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2006 3(2):75-78 ©2006 Ivyspring International Publisher. All rights reserved Review Antiviral therapy of HCV in the cirrhotic and transplant candidate Steven K. Herrine, and Victor J. Navarro Divisio[r]

therapy early in the course of HCV. Importantly a predictor of interferon response was an absence of treatment for acute rejection [28]. At our institution, patients with HCV undergo protocol liver biopsies every 6 months, and interferon and ribavirin are started only in the presence of progressive[r]

References 1. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35: 19-22. 2. IARC. Infection with Helicobacter pylori. In: IARC monographs on the evaluation of the carcinogenic risks to humans. Lyon, France: International Agency for Rese[r]

association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96. 10. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient s[r]

hepatitis C virus to CD81. Science 1998; 282: 938-41. 25. Agnello V, Abel G, Elfahal M, Knight GB and Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766-71. 26. Scarselli E, Ansuini H, Cerino R,[r]

as assessed by an HCV RNA assay with a lower limit of detection of 50 IU/ml or less 24 weeks after the end of treatment [18]. Initiation of therapy Only patients with detectable HCV RNA should be considered for pegylated IFN alfa and ribavirin combination therapy [18]. The decision to treat patients[r]

randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55. 27. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992;15(4):567-71. 28. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients wi[r]

with HCV or HBV. However, until now there is no standard of care available for treatment of patients with coinfection. Further clinical trails are needed to clarify the optimal treatment for such patients. Moreover, HCV genotype and HBV genotype were found to be associated with clinical outcome in s[r]

2. Metabolic Steatosis The etiology for hepatic steatosis can be determined by the distribution and size of the lipid accumulation within the hepatocytes. Microvesicular steatosis that is seen in Reye’s syndrome and Acute Fatty Liver Disease of Pregnancy occurs due to dysfunctions in β-oxidat[r]

Sweden. Acta Paediatr Scand 1982;293:1-21. 4. Silver RI, Rodriguez R, Chang TS, Gearhart JP. In vitro fertilization is associated with an increased risk of hypospadias. J Urol 1999;161:1954-7. 5. Czeizel A. Increasing trends in congenital malformations of male external genitalia. Lancet 1985;1:462-3[r]

Int. J. Med. Sci. 2006, 3 75International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2006 3(2):75-78 ©2006 Ivyspring International Publisher. All rights reserved Review Antiviral therapy of HCV in the cirrhotic and transplant candidate Steven K. Herrine, and Victor J. Navarro Divisio[r]

non-responders to peginterferon alpha 2b and ribavirin. In: AASLD (Abstract 413); Oct 29- Nov 2 2004; Boston, MA. 36. Gross JB et al. Renew Trial- High dose re-treatment with peginterferon alpha 2b plus ribavirin for non responders in chronic HCV patients. In: AASLD 2003 (Abstract 321); Oct 24-28 20[r]